Autopsy report · NCT01118975

GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers

“Lost sponsorship for study drug”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 2 years 7 months before it stopped.
• 12 participants enrolled.
• Results were posted on the registry 1 year 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

University of Maryland, Baltimore

Sponsor type

University, hospital or other

Conditions

Breast Cancer; Neoplasm Metastasis

Interventions

Vorinostat; Lapatinib

Participants

12

Sites

1

Countries

United States

Trials that died the same way

• Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
  “Drug no longer being supplied by sponsor” (77% match in meaning)
• Duet TRS Used in Pulmonary Resections
  “Sponsor is no longer pursuing this study” (75% match in meaning)
• Parkinson's Disease G2019S LRRK2 Genetic Testing Program
  “Sponsor stopped the study” (74% match in meaning)
• Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis
  “Sponsor stops to provide the study drug.” (74% match in meaning)
• Intravenous Ketamine Effects on Functional Neuroanatomy
  “Sponsor is no longer interested in funding the study” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.